Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company, announced today that the first patient ...
Low-dose aspirin reduced colorectal cancer (CRC) recurrence rates by more than half in patients with tumors harboring mutations in the PI3K signaling pathway, according to findings from the phase 3 ...
WNT pathway alterations in bevacizumab-treated early-onset colorectal cancer: An artificial intelligence–driven and disparity-aware precision oncology analysis. Longitudinal clinical validation of the ...
A groundbreaking study reveals that a daily low dose of aspirin can significantly reduce the risk of colorectal cancer ...
Aspirin reduces the risk of colon cancer recurrence after surgery, but only in patients with a specific genetic marker ...
Safety was described as manageable for both doublet and triplet regimens with no new signals, supporting feasibility of comprehensive pathway targeting in metastatic disease. Company plans include an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results